The favorable toxicology data removes a key overhang and supports IND submission. Traders should watch for IND filing in Q4 2026 and potential partnership interest given the obesity market size. The stock has high binary risk given early-stage status.
Price Chart
Executive Summary
Neumora Therapeutics announced favorable pre-clinical toxicology results for NMRA-215, a brain-penetrant oral NLRP3 inhibitor for obesity and cardiometabolic disease. A repeat 13-week rat study showed no unexpected adverse findings, resolving concerns from a prior study where 5 of 142 animals had issues. The company plans to submit an IND in Q4 2026 and initiate a clinical study in 2026.
Key Facts
- Repeat 13-week rat toxicology study (n=162) showed no unexpected in-life adverse findings, resolving prior concerns from a study where 5 of 142 animals had issues.
- Company plans to submit an IND for NMRA-215 in Q4 2026 and initiate a clinical study in 2026.
- NMRA-215 demonstrated class-leading weight loss as monotherapy in a diet-induced obesity mouse model, additive weight loss with semaglutide, and improved peripheral cardiometabolic biomarkers.
- NMRA-215 is a potentially best-in-class, highly brain-penetrant, oral NLRP3 inhibitor targeting obesity and cardiometabolic disorders.
Financial Impact
Pre-clinical data de-risks NMRA-215, a potential blockbuster obesity asset. No financial figures disclosed.
Risk Factors
- Histopathology report for the 3-month toxicity study is still pending, which could reveal new issues.
- Pre-clinical efficacy may not translate to humans; clinical trial risks remain high.
- Company is clinical-stage with no approved products; capital needs may require future dilution.
- Competition from GLP-1 drugs (semaglutide, tirzepatide) and other NLRP3 inhibitors.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3333375 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 20, 2026 6w ago | 144 | $1.63 $0.6918 | ▲ +57.56% | ▲ +57.03% | $0.4999 (+69.33%) |
Aug 17, 2026 6w ago | 144 | $1.64 $0.7732 | ▲ +52.85% | ▲ +51.54% | $0.4999 (+69.52%) |
Aug 14, 2026 7w ago | 8-K | $1.60 $0.9994 | ▼ −37.54% | ▼ −35.55% | $0.4999 (−68.76%) |
Aug 14, 2026 7w ago | Press Release | $1.60 $0.9994 | ▼ −37.54% | ▼ −35.55% | $0.4999 (−68.76%) |
Jul 27, 2026 9w ago | 8-K | $1.66 $1.53 | ▼ −8.13% | ▼ −11.43% | $0.4999 (−69.89%) |
Jul 27, 2026 9w ago | Press Release | $1.66 $1.53 | ▼ −8.13% | ▼ −11.43% | $0.4999 (−69.89%) |
Jun 15, 2026 15w ago | 8-K | $0.9145 $1.60 | ▼ −74.96% | ▼ −75.71% | $0.4999 (+45.34%) |
Apr 17, 2026 24w ago | DEFA14A | $2.19 $1.77 | ▼ −19.18% | ▼ −23.38% | $0.4999 (−77.17%) |
Mar 30, 2026 26w ago | Press Release | $1.93 $2.25 | ▲ +16.58% | ▲ +3.98% | $0.4999 (−74.10%) |
Mar 16, 2026 28w ago | Press Release | $2.87 $2.03 | ▼ −29.27% | ▼ −33.05% | $0.4999 (−82.58%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access